NVCR News and Press, NovoCure Limited From 10/31/19

NovoCure Limited (NVCR) Q3 2019 Earnings Conference Call October 31, 2019 8:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chief...

Image source: The Motley Fool. NovoCure Limited   (NASDAQ: NVCR) Q3 2019 Earnings Call Oct 31, 2019 , 8:00 a.m. ET Operator Continue reading

The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q3 earnings Read more ...

Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial mar...

NovoCure (NASDAQ: NVCR ) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is -$0.04 (+69.2% Y/Y) and the consensus Revenue Estimate is $87.12M (+34.5% Y/Y). Over the last 1 year, nvcr has beaten EPS estimates 0% of...

Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine m...

Introduction: Novocure ( NVCR ) is a mid-cap medical devices company which has a growing pipeline of clinical trials to treat cancer patients with its Tumor Treating Fields. Successful clinical trials in Glioblastoma have now led the treatment to be commercially available . The company is c...

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and...

The following slide deck was published by NovoCure Limited in conjunction with this Read more ...